An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

Inclusion Criteria: * The Participant has completed 52-weeks on the ALKS 3831-A313 clinical study. * The Participant must not be a danger to self or others (per Investigator judgement) and has family support available to be maintained as an outpatient. * The Participant will benefit from continued therapy with OLZ/SAM per the clinical judgment of the Participant's Physician. * The Participant can be treated on an outpatient basis. * The Participant agrees to abide by the contraception requirements specified in the protocol for the duration of the study. * The Participant's parent(s)/legal guardian(s) is/are considered reliable by the Physician and has agreed to provide support to the subject to ensure compliance with study treatment, visits, and protocol procedures. Exclusion Criteria: * The participant is eligible for commercial OLZ/SAM (LYBALVI®) through standard commercial pathways (≥18) for approved use. * The participant is at a current risk of suicidal behavior as assessed by the Participant's Physician or answered "Yes" to questions 4 or 5 on the C-SSRS and/or had a suicide attempt within the past 12 months. * The participant has any finding that in the view of the Physician would compromise the safety of the Participant or affect their ability to fulfill the Program requirements. * The participant is currently taking medications that are contraindicated with olanzapine or OLZ/SAM use or exhibit drug interaction potential with olanzapine or OLZ/SAM (such as the Part…